Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Eye Drops & Ophthalmic Recalls

Recalls of ophthalmic solutions and eye drops - a category hit by widely reported contamination recalls.

673 recalls in this category, newest first.

Class II · Moderate risk

Timolol Maleate Ophthalmic Solution USP

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

Ongoing Packaging defect FDC Limited NDC 64980-514-01 D-0403-2025
Class II · Moderate risk

Ciprofloxacin Ophthalmic Solution USP

Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect FDC Limited NDC 69315-308-05 D-0282-2025
Class II · Moderate risk

Timolol Maleate Ophthalmic Solution USP

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

Ongoing Packaging defect FDC Limited NDC 64980-514-05 D-0214-2025
Class II · Moderate risk

Ciprofloxacin Ophthalmic Solution USP

Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect FDC Limited NDC 69315-308-05 D-0182-2025
Class II · Moderate risk

Timolol Maleate Ophthalmic Solution USP

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

Ongoing Packaging defect FDC Limited NDC 64980-513-15 D-0114-2025
Class II · Moderate risk

Timolol Maleate Ophthalmic Solution USP

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect FDC Limited NDC 64980-514-05 D-0035-2025
Class II · Moderate risk

Refresh P.M.

Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

Ongoing Sterility / contamination AbbVie Inc. D-0664-2024